InfuSystem Holdings, Inc. (NYSE:INFU) Shares Bought by Barclays PLC

Barclays PLC boosted its position in shares of InfuSystem Holdings, Inc. (NYSE:INFUFree Report) by 300.5% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 28,597 shares of the company’s stock after acquiring an additional 21,457 shares during the quarter. Barclays PLC’s holdings in InfuSystem were worth $192,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Geode Capital Management LLC lifted its holdings in shares of InfuSystem by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 436,508 shares of the company’s stock valued at $2,925,000 after buying an additional 7,550 shares during the period. State Street Corp lifted its holdings in shares of InfuSystem by 1.1% in the 3rd quarter. State Street Corp now owns 267,012 shares of the company’s stock valued at $1,789,000 after buying an additional 3,019 shares during the period. BNP Paribas Financial Markets lifted its holdings in shares of InfuSystem by 66.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 4,076 shares of the company’s stock valued at $27,000 after buying an additional 1,626 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of InfuSystem in the 3rd quarter valued at about $87,000. Finally, Oppenheimer Asset Management Inc. lifted its holdings in shares of InfuSystem by 28.0% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 33,337 shares of the company’s stock valued at $223,000 after buying an additional 7,295 shares during the period. Institutional investors and hedge funds own 71.13% of the company’s stock.

Insider Activity at InfuSystem

In other InfuSystem news, CEO Richard Dilorio sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $9.32, for a total transaction of $186,400.00. Following the completion of the sale, the chief executive officer now directly owns 436,659 shares in the company, valued at approximately $4,069,661.88. The trade was a 4.38 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.20% of the stock is owned by company insiders.

InfuSystem Stock Up 3.1 %

Shares of InfuSystem stock opened at $8.23 on Wednesday. The company has a current ratio of 1.98, a quick ratio of 1.59 and a debt-to-equity ratio of 0.50. InfuSystem Holdings, Inc. has a twelve month low of $5.74 and a twelve month high of $10.03. The company has a 50-day simple moving average of $8.54. The stock has a market cap of $174.97 million, a price-to-earnings ratio of 137.19 and a beta of 1.53.

InfuSystem (NYSE:INFUGet Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.08 earnings per share for the quarter, meeting the consensus estimate of $0.08. InfuSystem had a return on equity of 2.78% and a net margin of 1.12%. The firm had revenue of $35.32 million during the quarter, compared to analyst estimates of $35.50 million. On average, sell-side analysts expect that InfuSystem Holdings, Inc. will post 0.15 EPS for the current year.

Wall Street Analyst Weigh In

INFU has been the subject of several analyst reports. B. Riley initiated coverage on InfuSystem in a report on Thursday, September 26th. They issued a “buy” rating and a $13.00 price objective for the company. StockNews.com raised InfuSystem from a “buy” rating to a “strong-buy” rating in a report on Friday, November 8th.

Check Out Our Latest Report on INFU

InfuSystem Company Profile

(Free Report)

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.

Further Reading

Want to see what other hedge funds are holding INFU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for InfuSystem Holdings, Inc. (NYSE:INFUFree Report).

Institutional Ownership by Quarter for InfuSystem (NYSE:INFU)

Receive News & Ratings for InfuSystem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InfuSystem and related companies with MarketBeat.com's FREE daily email newsletter.